# (19) World Intellectual Property Organization International Bureau



### 

### (43) International Publication Date 23 October 2003 (23.10.2003)

### **PCT**

## (10) International Publication Number WO 2003/087070 A3

(51) International Patent Classification<sup>7</sup>: A61K 38/04

C07K 5/00,

(21) International Application Number:

PCT/US2003/008821

- (22) International Filing Date: 31 March 2003 (31.03.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

,	I Horny Data.		
	0208116.4	9 April 2002 (09.04.2002)	GB
	60/371,271	9 April 2002 (09.04.2002)	US
	0208117.2	9 April 2002 (09.04.2002)	GB
	60/371,270	9 April 2002 (09.04.2002)	US
	0208118.0	9 April 2002 (09.04.2002)	GB
	60/371,278	9 April 2002 (09.04.2002)	US
	0208119.8	9 April 2002 (09.04.2002)	GB
	60/371,275	9 April 2002 (09.04.2002)	US
	0208120.6	9 April 2002 (09.04.2002)	GB
	60/371,277	9 April 2002 (09.04.2002)	US

- (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): EVERS, Britta [DE/DE]; Lilly Forschung, Essener Strasse 93, 22419 Hamburg (DE). RUEHTER, Gerd [DE/DE]; Lilly Forschung, Essener Strasse 93, 22419 Hamburg (DE). MARTIN DE LA NAVA, Eva, Maria [ES/ES]; Lilly, S. A., Avenida de la Industria 30, 28100 Alcobendas (ES). TEBBE, Mark, Joseph [US/DE]; Lilly Forschung, Essener Strasse 93, 22419 Hamburg (DE).

- (74) Agent: SALES, James, J.; Eli Lilly and Company, P.O.Box 6288, Indianapolis, IN 46206-6288 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declarations under Rule 4.17:


- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

#### Published

with international search report

[Continued on next page]

### (54) Title: GROWTH HORMONE SECRETAGOGUES



(57) Abstract: This invention relates to novel compounds of formula I wherein Q is SO<sub>2</sub> or -CO-which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.